



# Gwybod beth sy'n gweithio....



**Martin Landray** @MartinLandray · 8 Oct 2020

The **RECOVERY trial** has now answered 3 questions for hospitalised COVID pts:

- HCQ is not effective
- Lopinavir is not effective
- **Dexamethasone** reduces mortality for patients on oxygen or mechanical ventilators

All 3 results have changed medical practice & benefited patients



**OxPrimaryCareSci**  
@OxPrimaryCare

BREAKING NEWS: PRINCIPLE trial reports the corticosteroid budesonide is the first widely available, inexpensive drug found to shorten recovery time in non-hospitalised patients with COVID-19. It is now available in UK #primarycare on a case-by-case basis. [principletrial.org/news/asthma-dr...](https://principletrial.org/news/asthma-dr...)

**GenOMICC Study** @GenomiccStudy · Dec 11, 2020

The GenOMICC study has now found 5 DNA changes that make people susceptible to life-threatening COVID-19. These changes are linked to 5 genes and in some cases lead us directly to therapeutic targets. (3/8)



**University of Oxford**  
@UniofOxford

VACCINE UPDATE: New study shows that the #OxfordVaccine offers protection of 76% up to 12 weeks after a single dose, with further data supporting a 4-12 week dosing interval:



**Peter Horby** @PeterHorby · Nov 19, 2020

🔥 news on tocilizumab treatment in critically ill COVID-19 patients- REMAP-CAP declaring better [twitter.com/remap\\_cap/stat...](https://twitter.com/remap_cap/stat...)

# ....a beth sydd ddim yn gweithio



Ymchwil Iechyd  
a Gofal **Cymru**  
Health and Care  
Research **Wales**



**Peter Horby** @PeterHorby · Dec 14, 2020

New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1.00; 95% confidence interval [CI] 0.90-1.12; p=0.99). No effect on secondary outcomes either.

[medrxiv.org/content/10.110...](https://medrxiv.org/content/10.110...)



**Martin Landray**  
@MartinLandray

On the advice of the DMC, recruitment to the convalescent plasma arm of the RECOVERY trial has now closed:

Preliminary analysis: No convincing evidence of worthwhile mortality benefit either overall or in any pre-specified subgroup.



**remap-cap** @remap\_cap · Dec 23, 2020

On the recommendation of the Data Safety and Monitoring Board, #REMAPCAP has paused randomization to therapeutic #anticoagulation among critically ill patients with #COVID19 for futility.

6


236

298



# Cyflawni ymchwil COVID-19

Sefydlu ac agor 94 o astudiaethau COVID-19




**32** ASTUDIAETH IECHYD CYHOEDDUS BRYD  
COVID-19  
**36,500** o gyfranogwyr yng Nghymru



**112** o gleifion



**8** safle  
**1251** o gleifion



**6** safle  
**282** o gleifion




**3** Treial Brechlyn  
(**2** yn cael eu sefydlu)



15  
days to open to recruitment  
(UPH studies only)



7.5  
days (median) from opening  
to recruitment of 1st patient  
(UPH studies only)



# Rhaglen: Edrych i'r dyfodol gyda'n gilydd

## Dydd Mercher 21 Ebrill

13:15	Ymchwil ac Arloesedd mewn iechyd a gofal: dysgu o'r pandemig	Yr Athro Kieran Walshe, Cyfarwyddwr YIGC
13:35	Gweledigaeth y DU ar gyfer Ymchwil Glinigol	Carys Thomas, Llywodraeth Cymru
14:15	Cyfranogwr mewn Arolwg Profiad Ymchwil	Dr Andi Skilton, NIHR
14:35	Contractio a chyllido mewn model cenedlaethol	Dr Helen Hodgson, Fiona Dunn YIGC
15:15	Mewn gofod digidol: Beth mae'n ei olygu i ddyfodol cyflawni ymchwil?	Rachael Powell, NWIS
15:35	Trosolwg strategol o roi brechlynnau	Dr Andrew Freedman, Dr Orod Osanlou, Prif Ymchwilwyr

## Dydd Iau 22 Ebrill

09:15	Sicrhau bod Cymru yn rhan ganolog o ymchwil COVID-19 drwy gyfathrebu cydweithredol	Felicity Waters, YIGC
09:45	Cynorthwyo'r gymuned cartrefi gofal drwy ymchwil yn ystod pandemig a thu hwnt	Stephanie Green, ENRICH Cymru
10:15	Sut i sicrhau'r effaith fwyaf bosibl gyda gwahanol fathau o gynulleidfa	Ginger Training
11:05	HRA ac YIGC: arwain, dysgu ac adfer o COVID	Yr Athro Matt Westmore, HRA